Syndivia

Our vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment

[Syndivia @syndivia]

Syndivia Receives €2m Deeptech Financing From Bpifrance to Advance Its Lead Immunoconjugate for Solid Cancers https://t.co/8RBxwOMER4

[Bioconjugate Chem @BioconjChem]

The October 16th issue of BC is now available. https://t.co/uiXmB5qo7m Cover highlights review by Wagner Group @BFC_UMR7199 @BfcDovgan @sashakoniev https://t.co/zG5e5E2QGD

[Syndivia @syndivia]

Our review on applications and synthesis of Antibody–Oligonucleotide Conjugates (AOC) is online! Check it on the Bioconjugate Chemistry website:
https://t.co/vmLRPmPITA

[Syndivia @syndivia]

Syndivia’s CSO, Dr Sergii Kolodych, will be speaking at #PEGS Boston 2019. Catch a glimpse of our latest developments in the field of native protein conjugation on April 11 at Seaport World Trade Center, Boston, MA.

[Syndivia @syndivia]

Meet us at the 8th #WorldADC San Diego on September 20-22, 2017, and learn about exciting new conjugation technologies offered by @syndivia

[Bpifrance @Bpifrance]

France Tech Transfer: 12 startups sélectionnées pour participer au European Venture Summit à Düsseldorf https://t.co/Wch9H7MEVn @bymaddyness

[ROBERT Lucia @ROBERTLucia3]

Tout notre soutien aux projets @syndivia, @LMB_GlioCure et @Phostin accompagnés par @MATWIN_Bdx ! https://t.co/5bWl8nfPIU

[SATT CONECTUS @ConectusAlsace]

@ConectusAlsace & @syndivia signent une licence exclusive sur une technologie originale dans le traitement du cancer https://t.co/5Adk9Y5VAG

[SATT CONECTUS @ConectusAlsace]

@ConectusAlsace & @syndivia signent une licence exclusive sur une technologie originale dans le traitement du cancer https://t.co/5Adk9Y5VAG

[Syndivia @syndivia]

OGD2 Pharma and Syndivia launch collaboration to develop an ADC targeting the O-acetyl-GD2 cancer antigen
https://t.co/pOrLUeef8D

[Syndivia @syndivia]

Syndivia receives the EU’s Horizon 2020 grant for the development of next-generation targeted cancer therapies
https://t.co/WzRHfANuQj

[Syndivia @syndivia]

Syndivia signs distribution agreement with Sigma-Aldrich https://t.co/KFjqikAUbw

[Syndivia @syndivia]

Meet us at the SMi's annual ADC Summit, 23-24 May, London https://t.co/8D7BPWKI8N

[Syndivia @syndivia]

Syndivia is hiring a Research Associate in cell biology. For more details visit: http://t.co/qBVJGkA7kI

[Syndivia @syndivia]

Syndivia introduces a new route for the preparation of Antibody-Drug Conjugates in its recent scientific article : http://t.co/ROgHVoIltT

[Syndivia @syndivia]

Syndivia lands €275k grant to develop next-generation Antibody-Drug Conjugates http://t.co/lB46WueG9t

[Syndivia @syndivia]

Syndivia is among the TOP100 startups of the Hello Tomorrow Challenge http://t.co/sq1I7fsYSj

[Sasha Koniev @sashakoniev]

It’s about to start #HTC2015

[Syndivia @syndivia]

Syndivia is granted the prestigious MATWIN label http://t.co/pTvLhVz2BK

[Syndivia @syndivia]

A thorough review, published by Syndivia's co-founders, outlines recent advances in the field of bioconjugation http://t.co/1yIgViAZIW